CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to RHHBY

Ocrelizumab Test Formulation

Phase 2
Roche Holding AG (RHHBY)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Sep '26
RHHBYPhase 2

Ocrelizumab Test Formulation Phase 2 Est. Readout

Ocrelizumab Test Formulation
Sep 2026~
CT.gov
00%
Competitive Landscape
Drug Information

Target Indication

Multiple Sclerosis

Clinical Trial

NCT07074886

Last updated: 1/14/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMA1/8/2018

Ocrevus

Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.